1. Home
  2. FMN vs BMEA Comparison

FMN vs BMEA Comparison

Compare FMN & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Federated Hermes Premier Municipal Income Fund

FMN

Federated Hermes Premier Municipal Income Fund

HOLD

Current Price

$11.16

Market Cap

86.0M

Sector

Finance

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.47

Market Cap

87.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FMN
BMEA
Founded
2002
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
86.0M
87.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
FMN
BMEA
Price
$11.16
$1.47
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$8.71
AVG Volume (30 Days)
22.8K
1.0M
Earning Date
01-01-0001
11-04-2025
Dividend Yield
3.86%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.09
$0.87
52 Week High
$11.31
$4.59

Technical Indicators

Market Signals
Indicator
FMN
BMEA
Relative Strength Index (RSI) 56.60 60.49
Support Level $11.05 $1.23
Resistance Level $11.15 $1.37
Average True Range (ATR) 0.05 0.09
MACD 0.01 0.02
Stochastic Oscillator 94.37 74.65

Price Performance

Historical Comparison
FMN
BMEA

About FMN Federated Hermes Premier Municipal Income Fund

Federated Hermes Premier Municipal Income Fund is a United States-based diversified, closed-end management investment company. The investment objective of the fund is to provide current income exempt from federal income tax, including the federal alternative minimum tax by investing in long-term, tax exempt municipal bonds diversified among states, sectors and issuers. Its portfolio of investments comprises different sectors such as hospitals, toll road, senior care, airport, tobacco, and other sectors.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: